

Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments

Arneri?, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, *The Journal of Prevention of Alzheimer’s Disease* 4(4): 387.